<DOC>
	<DOCNO>NCT02857764</DOCNO>
	<brief_summary>The purpose study estimate incidence below-knee low extremity amputation type 2 diabetes mellitus ( T2DM ) participants newly expose sodium-glucose co-transporter 2 inhibitor ( SGLT2i ) / non-SGLT2i antihyperglycemic agent ( AHA ) overall subgroup high cardiovascular ( CV ) risk compare hazard below-knee low extremity amputation canagliflozin new user versus non-SGLT2i AHA new user .</brief_summary>
	<brief_title>Sodium-glucose Co-transporter 2 ( SGLT2 ) Inhibitor Risk Below-Knee Lower Extremity Amputation : A Retrospective Cohort Study Using Large Claims Database United States</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>First exposure particular drug person 's history For initial analysis , exposure start April 1 , 2013 January 31 , 2015 . For ongoing repeat analysis per protocol amendment , study period end date vary depending time data extraction analysis At least 365 day observation time prior index At least 1 condition occurrence 'Type II diabetes ' time index Exactly 0 condition occurrence 'Type I diabetes ' time index Participants amputation prior index date exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>